Skip to main content

Oxervate FDA Approval History

Last updated by Judith Stewart, BPharm on Aug 22, 2018.

FDA Approved: Yes (First approved August 22, 2018)
Brand name: Oxervate
Generic name: cenegermin-bkbj
Dosage form: Ophthalmic Solution
Company: Dompé farmaceutici SpA
Treatment for: Neurotrophic Keratitis

Oxervate (cenegermin) is a recombinant human nerve growth factor (rhNGF) ophthalmic solution indicated for the treatment of neurotrophic keratitis.

Before you use Oxervate, tell your doctor about all of your medical conditions, including if you:

Tell your doctor about all the medicines you take, including prescription and over-the counter medicines, vitamins, and herbal supplements.

How should I use Oxervate?

What should I avoid while using Oxervate?
Your vision may be blurred for a short time after using Oxervate. If this happens, wait until your vision clears before you drive or use machines.

Oxervate side effects
The most common side effect of Oxervate is eye pain, excess blood in the white of the eyes (ocular hyperemia), swelling (inflammation) of the eye, and increase of tears (increased lacrimation).

What are the ingredients in Oxervate?
Active ingredient: cenegermin-bkbj
Inactive ingredients: disodium hydrogen phosphate anhydrous, hydroxypropylmethyl cellulose, L-methionine, mannitol, polyethylene glycol 6000, sodium dihydrogen phosphate dihydrate, trehalose dihydrate, Water for Injection, USP, and hydrochloric acid and/or sodium hydroxide to adjust pH.

Development timeline for Oxervate

DateArticle
Aug 22, 2018Approval FDA Approves Oxervate (cenegermin) for Neurotrophic Keratitis

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.